Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02717533
Other study ID # 01249-B
Secondary ID
Status Completed
Phase N/A
First received February 4, 2015
Last updated March 22, 2016
Start date January 2014
Est. completion date January 2015

Study information

Verified date March 2016
Source VA New York Harbor Healthcare System
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Observational

Clinical Trial Summary

The objective of the proposed study is to demonstrate that serial blood volume analysis (BVA) using RI-BVA (BVA-100, Daxor, NY) can be used to guide changes in prescription of dry weight for hemodialysis patients. The knowledge of a patient's ideal BV and degree of hypervolemia using these measurements can be used to change the prescription of DW in an objective way instead of the current standard of practice, which is based on subjective prescription of dry weight. A first study was conducted to determine the rate of plasma volume (PV) re-expansion for each patient as a guide to rate of fluid removal (results published, refer to citations). A second study was conducted in order to assess the value of a BVA measurement in guiding prescription of clinical DW. A follow up BVA would then be done in order to check if patients were closer to ideal BV than prior to changing dry weight.


Description:

In the first study the investigators demonstrated that BV measurement using BVA-100 is useful to determine absolute BV as well as changes in BV and correlates reasonably well with CLM-III measurements. Individual refilling ability can be determined as well. This may prove useful in prescribing and monitoring ultrafiltration rates, establishment of optimal BV in HD patients and reducing morbidity and mortality associated with chronic HD.

In the current study the investigators hypothesize that BVA can be used in the longer term to evaluate the adequacy of the current clinically estimated dry weight in dialysis patients and can be used to titrate EDW in order to improve overall volume status and decrease the incidence of blood volume misinterpretation. The investigators enrolled 12 eligible patients. Participants underwent post-hemodialysis blood volume analysis (BVA) as a baseline measurement. Based on their Blood Volume (BV) status, their prescribed estimated dry weight (EDW) was adjusted. After 3 to 6 months, participants underwent a repeat BV measurement. The investigators compared the second value to the first in order to judge whether an improvement in BV status occurred if the dry weight prescription was changed, or to judge stability if it was not.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date January 2015
Est. primary completion date October 2014
Accepts healthy volunteers No
Gender Both
Age group 21 Years and older
Eligibility Inclusion Criteria:

- Age >21 years

- Primary diagnosis of either chronic or acute kidney disease

- Currently receiving HD treatment

- Thrice-weekly or twice-weekly HD schedule

- Treated with standard bicarbonate HD for at least the preceding 6 months

Exclusion Criteria:

- Pregnant women or nursing mothers

- Known hypersensitivity to iodine, eggs, albumin or any other component of the Volumex injection kit

- Current enrollment in another investigational treatment protocol for dialysis

- Kidney transplantation

- Malignancy requiring chemotherapy

- Unmeasurable blood pressure with a sphygmomanometer

- Active hematological disease

- Active gastrointestinal bleeding

- Severe malnutrition (predialysis serum albumin <2.6 g/dL)

- Persistent condition of intradialytic blood pressure instability (hypotensive episodes in >80% of regular dialysis sessions) within the previous one month period

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Other:
dry weight adjustment
dry weight change to match ideal blood volume obtained by blood volume measurement.

Locations

Country Name City State
United States New York Harbor VA Healthcare System Hemodialysis Unit New York New York

Sponsors (2)

Lead Sponsor Collaborator
VA New York Harbor Healthcare System Daxor Corporation

Country where clinical trial is conducted

United States, 

References & Publications (1)

Puri S, Park JK, Modersitzki F, Goldfarb DS. Radioisotope blood volume measurement in hemodialysis patients. Hemodial Int. 2014 Apr;18(2):406-14. doi: 10.1111/hdi.12105. Epub 2013 Nov 22. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Serial measurements of absolute blood volume before and after a hemodialysis treatment to achieve the target DW at which post-HD BV equals ideal BV To demonstrate that serial BVA using the Blood Volume Analyzer (BVA-100) can be used to guide changes in prescription of DW for HD patients in an objective way instead of the current standard of practice, which is based on subjective prescription of dry weight. The results obtained from this first study have been published (see references) and show good correlation with CLM-III measurements and can estimate individual refilling ability 6 months No
Primary Serial measurements of absolute blood volume 3-6 months apart to achieve the target DW at which post-HD BV equals ideal BV To demonstrate that serial BVA using the Blood Volume Analyzer (BVA-100) can be used to guide changes in prescription of DW for HD patients in an objective way so that post-dialysis weight reaches the patient's true dry weight. The other main objective is to study the correlation between change in post-dialysis weights and change in BV status as determined by BVA. This outcome will be looked at for all patients and also in the subgroups of patients who had their dry weight changed according to initial BVA measurement and in patients whose dry weight was kept the same after the initial measurement 6 months No
Secondary Incidence of dialysis complications and BV as determined by BVA Dialysis complications that are under investigation include intradialytic hypotension and cramps. The investigators compare the incidence of dialysis complications for patients across subgroups of BV status as determined by BVA. We will also compare the incidence of dialysis complication at baseline and at the second measurement 6 months No
Secondary Change in BV as determined by Crit-Line Monitor and reaching ideal BV by BVA For every patient the investigators record the relative change in BV as determined by Crit-line monitoring. The investigators compare the relative BV change in patients who are euvolemic by BVA to those who are considered to be volume depleted and to the ones that are volume overloaded 6 months No
See also
  Status Clinical Trial Phase
Completed NCT04510090 - Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus Phase 1
Completed NCT02546037 - Clotting With Different Dialyzer Membranes
Recruiting NCT02545920 - To Assess Ear Blood Flow During Dialysis
Completed NCT02134314 - C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI Phase 1/Phase 2
Recruiting NCT01912001 - Virtual Ward for Home Dialysis N/A
Completed NCT01158742 - Live Kidney Donor Study -Renal Function Study N/A
Completed NCT00986947 - Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates Phase 2
Completed NCT00765661 - Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients Phase 2
Withdrawn NCT00807274 - Renal Function in Adults With Congenital Heart Disease. N/A
Completed NCT00369382 - Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients Phase 4
Completed NCT00183248 - Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients Phase 1/Phase 2
Enrolling by invitation NCT05324878 - Honoring Individual Goals and Hopes: Implementing Advance Care Planning for Persons With Kidney Disease on Dialysis
Completed NCT05272800 - BIS-guided Fluid Management in HD Patients N/A
Completed NCT03836508 - Effect of Dialysis Membranes on Inflammatory and Immune Processes in Hemodialysis N/A
Completed NCT01756508 - Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury Phase 2
Completed NCT03723668 - Kidney Transplant Outcome and Organ Acceptance Practice Pattern: A Nationwide Analyses in the US and France
Recruiting NCT04277377 - Nanoparticle for DSA Removal
Terminated NCT00450333 - Dynepo Infrequent Dosing Study Phase 3
Terminated NCT03840343 - Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease Phase 1
Recruiting NCT04714853 - Different Dialysis Modalities and Diet on Gastrointestinal Biome and Azotaemic Toxins